Nootropics: Preclinical results in the light of clinical effects; Comparison with tacrine

Critical Reviews in Neurobiology

Volumn 10, Issue 3-4, 1996, Pages 357-370

  Mondadori, Cesare ^a  

^a SANOFI   (France)

Author keywords

Aniracetam; Clinical; Nonresponders; Nootropics; Oxiracetam; Piracetam; Pramiracetam; Preclinical; Responders; Tacrine

Indexed keywords

ANIRACETAM; NOOTROPIC AGENT; OXIRACETAM; PIRACETAM; PRAMIRACETAM; TACRINE;

ALZHEIMER DISEASE; DEMENTIA; HUMAN; MEMORY; REVIEW;

EID: 0030461363     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v10.i3-4.40     Document Type: Review

References (85)

1. Giurgea, C. E., Moyensoons, F., and Emand, A. A., A Gaba-related hypothesis on the mechanism of action of the anti-motion sickness drugs, Arch Int. Pharmacodyn., 166, 379, 1967.
2. Giurgea, C. E., The 'nootropic' approach to the pharmacology of the integrative activity of the brain, Conditional Reflex, 8, 108, 1973.
3. Fröstl, W. and Maître, L., The families of cognition enhancers, Pharmacopsychiatry, 22 (Suppl.), 54, 1989.
4. Mondadori, C., In search of the mechanism of action of the nootropics: new insights and potential clinical implications, Life Sci., 55, 2171, 1994.
5. Vernon, M. W. and Sorkin, E. M., Piracetam: an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders, Drugs & Aging, 1, 17, 1991.
6. Giurgea, C. E. and Mouravieff-Lesuisse, F., Effet facilitateur du piracetam sur un apprentissage répétitif chez le rat, J. Pharmacol., 3, 17, 1972.
7. Cumin, R., Bandle, E. F., Gamzu, E., and Haefely, W. E., Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents, Psychopharmacology, 78, 104, 1982.
8. Banfi, S. and Dorigotti, L., Experimental behavioral studies with oxiracetam on different types of chronic cerebral impairment, Clin. Neuropharmacol., 9, 19, 1986.
9. Butler, D. E., Leonard, J. D., Caprathe, B. W., L'Italien, Y. J., Pavia, M. R., Hershenson, F. M., Poschel, P. H., and Marriott, J. G., Amnesia-reversal activity of a series of cyclic imides, J. Med. Chem., 30, 498, 1987.
10. Yamada, K., Inoue, T., Tanaka, M., and Furukava, T., Prolongation of latencies for passive avoidance responses in rats treated with aniracetam or piracetam, Pharmacol. Biochem. Behav., 22, 645, 1985.
11. Mondadori, C. and Petschke, F., Do piracetam-like compounds act centrally via peripheral mechanisms? Brain Res., 435, 310, 1987.
12. Sansone, M. and Oliverio, A., Avoidance facilitation by nootropics, Prog. Neuropsychopharmacol. Biol. Psychiatry, 13, 89, 1989.
13. Mondadori, C., Ducret, T., and Borkowski, J., How long does 'memory consolidation' take? New compounds can improve retention preformance, even if administered up to 24 hours after the learning experience, Brain Res., 555, 107, 1991.
14. Mondadori, C., Hengerer, B., Ducret, T., and Borkowski, J., Delayed emergence of effects of memory-enhancing drugs: implications for the dynamics of long-term memory, Proc. Natl. Acad. Sci., 91, 2041, 1994.
15. Poschel, B. P. H., Ho, P. M., Ninteman, F. W., and Callahan, M. J., Pharmacologic therapeutic window of pramiracetam demonstrated in behavior, EEG, and single neuron firing rats, Experientia, 41, 1153, 1985.
16. Murray, C. L. and Fibiger, H. C., The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task, Psychopharmacology, 89, 378, 1986.
17. Poschel, B. P. H., Marriott, J̇. G., and Gluckman, M. I., Pharmacology of the cognition activator pramiracetam (CI-879), Drugs. Exp. Clin. Res., IX, 853, 1983.
18. Martin, P. R., Cumin, R., Aschwanden, W., Moreau, J. L., Jenck, F., and Haefely, W. E., Aniracetam improves radial maze performance in rats, NeuroReport, 3, 81, 1992.
19. Pontecorvo, M. J. and Evans, H. L., Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons, Pharmacol. Biochem. Behav., 22, 745, 1985.
20. Ennaceur, A., Cavoy, A., Costa, J. C., and Delacour, J., A new one-trial test for neurobiological studies of memory in rats. II: effects of piracetam and pramiracetam, Brain Res., 33, 197, 1989.
21. Perio, A., Terranova, J. P., Worms, P., Bluthe, R. M., Dantzer, R., and Biziere, K., Specific modulation of social memory in rats by cholinomimetic and nootropic drugs, by benzodiazepine inverse agonists, but not by psychostimulants, Psychopharmacology, 97, 262, 1989.
22. Mondadori C, Lederer R, and Zingg M., Delayed emergence of oxiracetam-induced facilitation of long-term memory in the social-recognition test in rats, Psychopharmacology, in revision, 1996.
23. Mondadori, C., Ducret, T., and Häusler, A., Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics, Psychopharmacology, 108, 11, 1992.
24. Mondadori, C., The pharmacology of long-term memory, Eur. Rev., 3, 35, 1995.
25. Kuribara, H. and Tadokoro, S., Facilitating effect of oxiracetam and piracetam on acquisition of discrete two-way shuttle avoidance in normal mice, Jpn. J. Pharmacol., 48, 494, 1988.
26. Mondadori, C., Möbius, H.J., and Borkowski, J., The GABAB receptor antagonist CGP 36 742 and the nootropic oxiracetam facilitate the formation of long-term memory, Behav. Brain Res., 77, 223, 1996.
27. Sara, S. J., Memory retrieval deficits: alleviation by etiracetam, a nootropic drug, Psychopharmacology, 68, 235, 1980.
28. Xiao, P., Staubli, U., Kessler, M., and Lynch, G., Selective effects of aniracetam across receptor types and forms of synaptic facilitation in hippocampus, Hippocampus, 1, 373, 1991.
29. Spignoli, G. and Pepeu, G. C., Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine, Pharmacol. Biochem. Behav., 27, 491, 1987.
30. Pugsley, T. A., Poschel, B. P. H., Downs, D. A., Shih, Y.-H., and Gluckman, M. I., Some pharmacological and neurochemical properties of a new cognition activator agent, pramiracetam (CI-879), Psychopharmacol. Bull., 19, 721, 1983.
31. Mondadori, C., Gentsch, C., Hengerer, B., Ducret, T., Borkowski, J., Racine, A., Lederer, R., and Häusler, A., Pretreatment with aldosterone or corticosterone blocks the memory-enhancing effects of nimodipine, captopril, CGP 37849, and strychnine in mice, Psychopharmacology, 109, 383, 1992.
32. Mondadori, C. and Etienne, P., Nootropic effects of ACE-inhibitors in mice, Psychopharmacology, 100, 301, 1990.
33. Ennaceur, A. and Meliani, K., Effects of physostigmine and scopolamine on rats' performances in object-recognition and radial-maze tests, Psychopharmacology, 109, 321, 1992.
34. Croisile, B., Trillet, M., Fondarai, J., Laurent, B., Mauguiere, F., and Billardon, M., Long-term and high-dose piracetam treatment of Alzheimer's disease, Neurology, 43, 301, 1993.
35. Claus, J. J., Ludwig, M. D., Mohr, E., Giuffra, M., Blin, J., and Chase, T. N., Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam, Neurology, 41, 570, 1991.
36. Mangoni, A., Perin, C., Smirne, S., Piccolo, I., De Filippi, F., Marchetti, C., Motta, A., and Monza, G. C., A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska neuropsychological battery, Drug Dev. Res., 14, 217, 1988.
37. Molloy, D. W., Guyatt, G., and Brown, G., Effects of oxiracetam on cognition, behaviour and activities of daily living in dementia, J. Clin. Exp. Gerontol., 14, 217, 1992.
38. Senin, U., Abate, G., Fieschi, C., Gori, G., Guala, A., Marini, G., Villardita, C., and Parnetti, L., Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer's type (SDAT): results of a placebo controlled multicentre clinical study, Eur. Neuropsychopharmacol., 1, 511, 1991.
39. Villardita, C., Grioli, S., Lomeo, C., Cattaneo, C., and Parini, J., Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multiinfarct dementia of mild to moderate degree, Neuropsychobiology, 25, 24, 1992.
40. Bottini, G., Vallar, G., Cappa, S., Monza, G., Scarpini, E., Baron, P., Cheldi, A., and Scarlato, G., Oxiracetam in dementia: a double-blind, placebo-controlled study, Acta Neurol. Scand., 86, 237, 1992.
41. Maina, G., Fiori, L., Torta, R., Fagiani, M. B., Ravizza, L., Bonavita, E., Ghiazza, B., Teruzzi, F., Zagnoni, P. G., and Ferrario, E., Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study, Neuropsychobiology, 21, 141, 1989.
42. Moglia, A., Sinforiani, E., Zandrini, C., Gualtieri, S., Corsico, R., and Arrigo, A., Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study, Clin. Neuropharmacol., 9 (Suppl.), 3, 73, 1986.
43. Baumel, B., Eisner, L., Karukin, M., MacNamara, R., Katz, R. J., and Deveaugh-Geis, J., Oxiracetam in the treatment of multi-infarct dementia, Prog. Neuropsychopharmacol. Biol. Psychiatry, 13, 673, 1989.
44. Lloyd-Evans, S., Brocklehurst, J. C., and Palmer, M. K., Piracetam in chronic brain failure, Curr. Med. Res. Opin., 6, 351, 1979.
45. Saletu, B., Linzmayer, L., Grünberger, H., and Pietschmann, H., Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life, Neuropsychobiology, 13, 44, 1985.
46. Itil, T. M., Menon, G. N., Bozak, M., and Songar, A., The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam), Drug Dev. Res., 2, 447, 1982.
47. Chouinard, G., Annable, L., Ross-Chouinard, A., Olivier, M., and Fontaine, F., Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment, Psychopharmacology, 81, 100, 1983.
48. Abuzzahab, F. S., Merwin, G. E., Zimmermann, R. L., and Sherman, M. C., A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory, Pharmacopsychiatry, 10, 49, 1977.
49. Mindus, P., Cronholm, B., Levander, S. E., and Schalling, D., Piracetam-induced improvement of mental performance: a controlled study of normally aging individuals, Acta Psychiatr. Scand., 54, 150, 1976.
50. Dimond, S. J. and Brouwers, E. Y. M., Increase in the power of human memory in normal man through the use of drugs, Psychopharmacology, 49, 307, 1976.
51. Aldenkamp, A. P., van Wieringen, A., Alpherts, W. C., van Emde-Boas, W., Haverkort, H. A., de Vries, J., and Meinardi, H., Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy, Neuropsychobiology, 24, 90, 1990.
52. Wilsher, C. R., Bennett, D., Chase, C. H., Connors, C. K., Dilanni, M., Feagans, L., Hanvik, L. J., Helfgott, E., Koplewicz, H., Overby, P., Reader, M. J., Rudel, R. G., and Tallal, P., Piracetam and dyslexia: effects on reading tests, J. Clin. Psychopharmacol., 7, 230, 1987.
53. Hjorther, A., Browne, E., Jakobsen, K., Viskum, P., and Gyntelberg, F., Organic brain syndrome treated with oxiracetam, Acta Neurol. Scand., 75, 271, 1986.
54. Somnier, F. E., Ostergaard, M. S., Boysen, G., Bruhn, P., and Mikkelsen, B. O., Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents, Psychopharmacology, 101, 43, 1990.
55. Carrington Da Costa, R. B., Maul, E. R., Pimentel, J., Cardoso d'Oliveira, L., Aranjo Lacerda, J. C., and Gomes, J. D., A controlled clinical study. Piracetam vs placebo in disorders of consciousness due to head injuries, Acta Ther., 4, 109, 1978.
56. McLean, A., Jr., Cardenas, D. D., Burgess, D., and Gamzu, E., Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia, Brain Inj., 5, 375, 1991.
57. Fleischhacker, W. W., Günther, V., Barnas, C., Lieder, F., and Miller, C., Piracetam in alcoholic organic mental disorder: a placebo-controlled study comparing two dosages, Int Clin. Psychopharmacol., 1, 210, 1986.
58. Lagergren, K. and Levander, S., A double-blind study on the effects of piracetam upon perceptual and psychomotor performance at varied heart rates in patients treated with artificial pacemakers, Psychopharmacologia, 39, 97, 1974.
59. Dager, S. R., Loebel, J. P., Claypool, K., Case, M., Budech, C. B., and Dunner, D. L., Oxiracetam in the treatment of primary dementia of the Alzheimer's type: a small case series, Int. J. Geriatr. Psychiatry, 7, 905, 1992.
60. Branconnier, R. J., Cole, J. O., Dessain, E. C., Spera, K. F., Ghazvinian, S., and De Vitt, D., The therapeutic efficacy of pramiracetam in Alzheimer's disease: preliminary observations, Psychopharmacol. Bull., 19, 726, 1983.
61. Gallai, V., Mazzotta, G., Del Gatto, F., Montesi, S., Mazzetti, A., Dominici, P., and Della Monica, A., A clinical and neurophysiological trial on nootropic drugs in patients with mental decline, Acta Neurol., 13, 1, 1991.
62. Falsaperla, A., Monici-Preti, P. A., and Oliani, C., Selegiline versus oxiracetam in patients with Alzheimer-type dementia, Clin. Ther., 12, 376, 1990.
63. Ferrero, E., Controlled clinical trial of oxiracetam in the treatment of chronic cerebrovascular insufficiency in the elderly, Curr. Ther. Res., 36, 298, 1984.
64. Parnetti, L., Mecocci, P., Petrini, A., Longo, A., Buccolieri, A., and Senin, U., Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multiinfarct dementia in comparison with a control group, Neuropsychobiology, 22, 97, 1989.
65. Foltyn, P., Lucker, P. W., Schnitker, J., and Wetzelsberger, N., A test model for cerebrally active drugs as demonstrated by the example of the new substance aniracetam, Arzneim-Forsch/Drug Res., 33, 865, 1983.
66. Macchione, C., Molaschi, F., Fabris, F., and Feruglio, F. S., Results with piracetam in the management of senile psycho-organic syndromes, Acta Ther., 2, 261, 1976.
67. Parnetti, L., Bartorelli, L., Bonaiuto, S., Cucinotta, D., Cuzzupoli, M., Erminio, F., Maggioni, M., Marini, G., Paciaroni, E., Pedrazzi, F., Peruzza, M., and Senin, U., Aniracetam (Ro 13-5057) for the treatment of senile dementia of Alzheimer type: results of a multicentre clinical study, Dementia, 2, 262, 1991.
68. Green, R. C., Goldstein, F. C., Auchus, A. P., Presley, R., Clark, S., Van Tuyl, L., Green, J., Hersch, S. M., and Karp, H. R., Treatment trial of oxiracetam in Alzheimer's disease, Arch. Neurol., 49, 1135, 1992.
69. Davies, P. and Maloney, A. J. F., Selective loss of central cholinergic neurons in alzheimer's disease, Lancet, 2, 1403, 1976.
70. Summers, W. K., Majowski, V., Marsh, G. M., Tachiki, K., and Kling, A., Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer Type, N. Engl. J. Med., 315, 1241, 1986.
71. Davies, B., Andrewes, D., Stargatt, R., Ames, D., Tuckwell, V., and Davis, S., Tacrine in Alzheimer's disease, Lancet, July 15th, 1989.
72. Chatellier, G. and Lacomblez, L., Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicenter trial, Br. Med. J., 300, 495, 1990.
73. Gauthier, S., Bouchard, R., Lamontagne, A., Bailey, P., Bergman, H., Ratner, J., Tesfaye, Y., St-Martin, M., Bacher, Y., Carrier, L., Charbonneau, R., Clarfield, M., Collier, B., Dastoor, D., Gauthier, L., Germain, M., Kissel, C., Krieger, M., Kushnir, S., Masson, H., Morin, J., Nair, V., Neirinck, L., and Suissa, S., Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease, N. Engl. J. Med, 322, 1272, 1990.
74. Molloy, D. W., Guyatt, G. H., Wilson, D. B., Duke, R., Rees, L., and Singer, J., Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease, Can. Med. Assoc. J., 144, 29, 1991.
75. Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoower, T. M., Morris, J. C., Kawas, C. H., Knopman, D. S., Earl, N. L., Kumar, V., Doody, R. S., Tacrine Collaborative Study Group, A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, N. Engl. J. Med., 327, 1253, 1992.
76. Farlow, M., Gracon, S. I., Hershey, L. A., Lewis, K. W., Sadowsky, C. H., and Dolan-Ureno, J., A controlled trial of tacrine in Alzheimer's disease, JAMA, 268, 2523, 1992.
77. Eagger, S., Morant, N., Levy, R., Sahakian, B., Tacrine in Alzheimer's Disease. Time course of changes in cognitive function and practice effects, Br. J. Psychiatry, 160, 36, 1992.
78. Knapp, M., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., and Gracon, S. I., A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease, JAMA, 271, 991, 1994.
79. Maltby, N., Broe, G. A., Creasey, H., Jorm, A. F., Christensen, H., and Brooks, W. S., Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial, Br. Med. J., 308, 879, 1994.
80. Wilcock, G. K., Surmon, D. J., Scott, M., Boyle, M., Mulligan, K., Neubauer, K. A., O'Neill, D., and Royston, V. H., An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease, Age and Ageing, 22, 316, 1993.
81. Wood, P. C. and Castleden, C. M., A double-blind, placebo-controlled, multicentre study of tacrine for Alzheimer's disease, Int. J. Geriatr. Psychiatry, 9/8, 649, 1994.
82. Gustafson, L., Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease, Acta Neurol. Scand., 149 (Suppl.), 39, 1993.
83. Debert, W., Interaction between psychological and pharmacological treatment in cognitive impairment, Life Sci., 55, 2057, 1994.
84. Locke, K. W., Gorney, B., Cornfeldt, M., and Fielding, S., Characterization of the discriminative stimulus effects of physostigmine in the rat, J. Pharmacol. Exp. Ther., 250, 241, 1989.
85. Martignoni, E., Petraglia, F., Costa, A., Bono, G., Genazzini, A. R., and Nappi, G., Dementia of the Alzheimer type and hypothalamus pituitary-adrenocortical axis: changes in cerebrospinal fluid, corticotropin releasing factor, and plasma cortisol levels, Acta Neurol. Scand., 81, 452, 1990.